Disease modification in psoriasis

Authors

  • Tauseef Kamran Consultant Dermatologist, Department of Dermatology, Kot Khawaja Saeed Teaching Hospital Lahore/ King Edward Medical University Lahore.

DOI:

https://doi.org/10.66344/jpad.34.1.2024.2763

References

Griffiths CEM, Armstrong AW, Godjonsson JE, et al. Psoriasis. Lancet 2021;397(10281):1301-15.

Davidovici BB, Satter N,Jorg PC, et al. Psoriasis and systemic inflammatory diseases: Potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010; 130:1785-96.

Magina S, Felipe P, et al. Pathophysiology of moderate to severe plaque psoriasis: Anti IL-17 towards disease modification. Drugs Today. 2021;57(5):347-57.

Nasty A, Smith C, Spurs Pl, et al. EuroGuiDerm guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venerol. 2021;73(2):181-93.

Suarez Farinas M, Fuentes Duculan J, Lowes MA, et al. Resolved psoriasis lesions retain expression of a subset of disease related genes. J Invest Dermatol. 2011;131(2):391-400.

Mantos TR, O Malley JT, Lowery EL, et al. Clinically resolved psoriatic lesions contain psoriatic-specific IL-17 producing alpha beta cell clones. J Clinic Invest. 2017;127:4031-44.

Deane KD, Holers VM, Rheumatoid arthritis pathogenesis, perdiction, and prevention: An an emerging paradigm shift. Arthritis Rheumatol. 2021;73(2):181-93.

Berg DR, Colombia JF,Ungaro R, et al. The role of early biologic therapy in inflammatory bowel disease. Inf Bowel Dis. 2019;25(12):1896-905.

Hakim Ben A, Thomas E, Anna B, et al. Early intervention and disease memory in psoriasis: A literature review. J Euro Acad Dermatol Venerol. 2022;1(4):307-16.

Scherzo J U,Ogdie A, Merola J F, et al. Preventing psoriatic arthritis: Focusing on patients with psoriasis at risk of transition. Nat Rev Rheumatol. 2019;15:153-6.

Francesco B, Andera C, Stefano P, et al. Could targeted pharmacotherapies exert a ‘disease modification effect’ in patients with chronic plaque psoriasis. Int J Mol Sci. 2022;23(21):12849-64.

Published

2024-05-06

How to Cite

1.
Kamran T. Disease modification in psoriasis. J Pak Assoc Dermatol [Internet]. 2024May6 [cited 2026May2];34(1):1-2. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/2763

Issue

Vol. 34 No. 1 (2024): January-March

Section

Editorial

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.